Home > News > Clinical Trial of VivaGel for Genital Herpes
June 26th, 2006
Clinical Trial of VivaGel for Genital Herpes
Abstract:
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) today announced the submission of a second Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for a clinical trial of VivaGel™ (SPL7013 Gel). The clinical trial is in support of the product’s second clinical indication, prevention of genital herpes.
Source:
pipelinereview.com
Bookmark:
| Related Links |
| Related News Press |
Nanomedicine
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||